ATE522526T1 - 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen - Google Patents

4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen

Info

Publication number
ATE522526T1
ATE522526T1 AT08850039T AT08850039T ATE522526T1 AT E522526 T1 ATE522526 T1 AT E522526T1 AT 08850039 T AT08850039 T AT 08850039T AT 08850039 T AT08850039 T AT 08850039T AT E522526 T1 ATE522526 T1 AT E522526T1
Authority
AT
Austria
Prior art keywords
pain
treatment
oxopyrrolidine
thiazol
morpholino
Prior art date
Application number
AT08850039T
Other languages
English (en)
Inventor
Dean Stamos
Esther Martinborough
Timothy Neubert
Mehdi Numa
Tara Whitney
Nicole Zimmermann
Aarti Kawatkar
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE522526T1 publication Critical patent/ATE522526T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT08850039T 2007-11-13 2008-11-12 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen ATE522526T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98748507P 2007-11-13 2007-11-13
US8814108P 2008-08-12 2008-08-12
PCT/US2008/083165 WO2009064747A2 (en) 2007-11-13 2008-11-12 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain

Publications (1)

Publication Number Publication Date
ATE522526T1 true ATE522526T1 (de) 2011-09-15

Family

ID=40380263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08850039T ATE522526T1 (de) 2007-11-13 2008-11-12 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen

Country Status (13)

Country Link
US (3) US7994166B2 (de)
EP (1) EP2231655B1 (de)
JP (1) JP2011503112A (de)
KR (1) KR20100098396A (de)
CN (1) CN102036985A (de)
AT (1) ATE522526T1 (de)
AU (1) AU2008321137A1 (de)
CA (1) CA2705336A1 (de)
IL (1) IL205697A0 (de)
MX (1) MX2010005309A (de)
NZ (1) NZ585332A (de)
RU (1) RU2010123781A (de)
WO (1) WO2009064747A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
KR20080021030A (ko) * 2005-05-16 2008-03-06 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
JP2009507851A (ja) * 2005-09-09 2009-02-26 バーテックス ファーマシューティカルズ インコーポレイテッド 電位型イオンチャネルの調節因子としての二環式誘導体
WO2007050522A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
EP2158183A2 (de) 2007-05-25 2010-03-03 Vertex Pharmaceuticals Incorporated Ionenkanalmodulatoren und verfahren zur verwendung
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
US7994166B2 (en) 2007-11-13 2011-08-09 Vertex Pharmaceuticals Incorporated Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain
RU2010123876A (ru) * 2007-11-13 2011-12-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
US7846954B2 (en) * 2008-07-01 2010-12-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
AU2013209958B2 (en) * 2012-01-16 2017-09-07 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
RU2015114405A (ru) 2012-10-12 2016-11-27 Ф. Хоффманн-Ля Рош Аг Замещенные соединения фенилкарбамата
MX2015002024A (es) 2012-10-16 2015-06-22 Hoffmann La Roche Compuestos de carbamato substituidos y su uso como antagonistas del canal con potencial para el receptor transitorio (trp).
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
WO2018093694A1 (en) * 2016-11-17 2018-05-24 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
CN110446708B (zh) 2017-07-21 2022-12-02 安塔比奥公司 化学化合物
CN113008999A (zh) * 2019-12-19 2021-06-22 重庆药友制药有限责任公司 一种分离测定氟比洛芬酯中2种基因毒性杂质的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU2004240885A1 (en) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I
JP2007501804A (ja) 2003-08-08 2007-02-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
JP2007261945A (ja) * 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd チアゾール誘導体
RU2007145434A (ru) * 2005-05-10 2009-06-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов ионных каналов
KR20080021030A (ko) 2005-05-16 2008-03-06 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
US7683066B2 (en) 2005-05-20 2010-03-23 Vertex Pharmaceuticals Incorporated Isoquinolines useful as modulators of ion channels
WO2006133459A1 (en) * 2005-06-09 2006-12-14 Vertex Pharmaceuticals Incorporated Indane derivatives as modulators of ion channels
JP2009507851A (ja) 2005-09-09 2009-02-26 バーテックス ファーマシューティカルズ インコーポレイテッド 電位型イオンチャネルの調節因子としての二環式誘導体
ATE551333T1 (de) * 2005-10-12 2012-04-15 Vertex Pharma Biphenylderivate als modulatoren von spannungsabhängigen ionenkanälen
WO2007050522A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
CA2633653A1 (en) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
EP2158183A2 (de) 2007-05-25 2010-03-03 Vertex Pharmaceuticals Incorporated Ionenkanalmodulatoren und verfahren zur verwendung
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
US7994166B2 (en) 2007-11-13 2011-08-09 Vertex Pharmaceuticals Incorporated Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain
RU2010123876A (ru) * 2007-11-13 2011-12-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
US7846954B2 (en) 2008-07-01 2010-12-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels

Also Published As

Publication number Publication date
US20120010416A1 (en) 2012-01-12
AU2008321137A1 (en) 2009-05-22
WO2009064747A3 (en) 2010-08-19
US20130338119A1 (en) 2013-12-19
MX2010005309A (es) 2010-06-25
EP2231655B1 (de) 2011-08-31
US7994166B2 (en) 2011-08-09
NZ585332A (en) 2012-05-25
WO2009064747A2 (en) 2009-05-22
IL205697A0 (en) 2010-11-30
KR20100098396A (ko) 2010-09-06
US20090131440A1 (en) 2009-05-21
US8841282B2 (en) 2014-09-23
EP2231655A2 (de) 2010-09-29
JP2011503112A (ja) 2011-01-27
CN102036985A (zh) 2011-04-27
CA2705336A1 (en) 2009-05-22
RU2010123781A (ru) 2011-12-20

Similar Documents

Publication Publication Date Title
ATE522526T1 (de) 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20091626L (no) MGLUR5-modulatorer
EA200870569A1 (ru) Соединения и способы модуляции fxr
EA201400111A1 (ru) Ингибиторы mek и способы их применения
EA201290255A1 (ru) Способы и композиции для лечения рака
EA201070247A1 (ru) Ингибиторы протеасом
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
MXPA05010496A (es) Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
NO20061194L (no) Mitotiske kinesininbibitorer
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
ATE489088T1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid- derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
ATE383337T1 (de) 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1- phenylpropan-2-olderivate und verwandte verbindungen als modulatoren der norepinephrin- (ne-) und der serotonin-(5-ht-) aktivität und der monoaminwiederaufnahme zur behandlung von vasomotorischen symptomen (vms)
MX2009003763A (es) Inhibidores de metaloproteasa derivados de heterociclicos.
MX2010003009A (es) Piridil sulfonamidas como moduladores de canales ionicos.
NO20092691L (no) 4-hydroksy-2-okso-2,3-dihydro-1,3-benzotiazol-7yl-forbindelser for modulering av B2-adrenoreseptoraktivitet
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
ATE540036T1 (de) Heterocyclische derivate als ionenkanalmodulatoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2231655

Country of ref document: EP